Prognostic value of measurable residual disease at allogeneic transplantation for adults with core binding factor acute myeloid leukemia in complete remission-Reference-Cited by-同舟云学术

Prognostic value of measurable residual disease at allogeneic transplantation for adults with core binding factor acute myeloid leukemia in complete remission

Published:2021-07-16 Issue:11 Volume:56 Page:2779-2787
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Konuma Takaaki^ORCID,Kondo Tadakazu^ORCID,Masuko Masayoshi,Shimizu Hiroaki,Shiratori Souichi^ORCID,Fukuda Takahiro,Kato Jun^ORCID,Sawa Masashi,Ozawa Yukiyasu,Ota Shuichi^ORCID,Uchida Naoyuki^ORCID,Kanda Yoshinobu^ORCID,Kako Shinichi^ORCID,Fujisawa Shin,Fukushima Kentaro,Ichinohe Tatsuo^ORCID,Atsuta Yoshiko^ORCID,Yanada Masamitsu^ORCID,

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

https://www.nature.com/articles/s41409-021-01409-4.pdf

Reference38 articles.

1. Schuurhuis GJ, Heuser M, Freeman S, Béné MC, Buccisano F, Cloos J, et al. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood 2018;131:1275–91.

2. Dillon R, Potter N, Freeman S, Russell N. How we use molecular minimal residual disease (MRD) testing in acute myeloid leukaemia (AML). Br J Haematol. 2021;193:231–44.

3. Cloos J, Ossenkoppele GJ, Dillon R. Minimal residual disease and stem cell transplantation outcomes. Hematol Am Soc Hematol Educ Program. 2019;2019:617–25.

4. Gaut D, Mead M. Measurable residual disease in hematopoietic stem cell transplantation-eligible patients with acute myeloid leukemia: clinical significance and promising therapeutic strategies. Leuk Lymphoma. 2021;62:8–31.

5. Yin JA, O’Brien MA, Hills RK, Daly SB, Wheatley K, Burnett AK. Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial. Blood 2012;120:2826–35.

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prophylactic therapy using epigenetic agents for RUNX1::RUNXT1-positive high-risk AML after Allo-HSCT;Annals of Hematology;2024-06-22

2. Biological Characteristics and Treatment Progress of Adult Acute Myeloid Leukemia;Advances in Clinical Medicine;2024

3. The core concepts of core binding factor acute myeloid leukemia: Current considerations for prognosis and treatment;Blood Reviews;2023-11

4. Acute myeloid leukaemia;The Lancet;2023-06

5. Application of prophylactic or pre-emptive therapy after allogeneic transplantation for high-risk patients with t(8;21) acute myeloid leukemia;Hematology;2023-04-27